GE Healthcare reports positive data from MultiOmyx study

GE Healthcare has announced results from two studies that showing how its MultiOmyx pathology platform can further understanding of various cancer types.

The studies assessed the commercially available MultiOmyx Hodgkin Lymphoma Profile and an investigational profile for breast cancer, revealing how the technology can improve assessment of the two diseases in subsets of patients.

Using proprietary methodology to assess multiple proteins in a tissue section at a single-cell level, while preserving tissue context, the platform provided more accurate results and easier comparison of different samples.

Dr Christine Kuslich, chief scientific officer for in vitro diagnostics at GE Healthcare Life Sciences, said this data shows how its technology can be used to help researchers "gain a much deeper understanding of what can be seen in a tumour, on a slide, region of interest or at a cellular level in a variety of cancers".

MultiOmyx was created by GE Healthcare subsidiary Clarient Diagnostic Services, which was purchased by the group in 2010.